Covid 19 Research using Clinical Trials (Home Page)
Report for D004417: Dyspnea NIH
(Synonyms: Dyspnea)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (13)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1304 | Standard-of-care Wiki | 0.45 |
| drug590 | Hydrogen Oxygen Generator with Nebulizer Wiki | 0.45 |
| drug413 | Delayed diagnostics Anyplex TMII RV16 Detection Wiki | 0.45 |
| drug120 | Aviptadil (VIP) Wiki | 0.45 |
| drug494 | Experimental drug Wiki | 0.45 |
| drug1129 | Rapid diagnostics using Anyplex TMII RV16 Detection Wiki | 0.45 |
| drug401 | Data Collection Wiki | 0.32 |
| drug1367 | Telmisartan Wiki | 0.32 |
| drug893 | Nitric Oxide Wiki | 0.26 |
| drug393 | DAS181 Wiki | 0.22 |
| drug129 | Azithromycin Wiki | 0.08 |
| drug591 | Hydroxychloroquine Wiki | 0.05 |
| drug1016 | Placebo Wiki | 0.03 |
Correlated MeSH Terms (13)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005335 | Fever of Unknown Origin NIH | 0.45 |
| D002637 | Chest Pain NIH | 0.45 |
| D014947 | Wounds and Injuries NIH | 0.13 |
| D055370 | Lung Injury NIH | 0.10 |
| D011024 | Pneumonia, Viral NIH | 0.06 |
| D055371 | Acute Lung Injury NIH | 0.05 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.05 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.05 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D011014 | Pneumonia NIH | 0.03 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.02 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002098 | Respiratory distress HPO | 1.00 |
| HP:0100749 | Chest pain HPO | 0.45 |
| HP:0002090 | Pneumonia HPO | 0.03 |
There are 5 clinical trials
Clinical Trials
1 The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial
Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs. A small portion of the infections leads to severe clinical manifestations including hospitalisations and deaths. The significance of influenza virus is well known and it is actively detected in all age groups. However, the benefits of detecting other respiratory viruses have mainly been studied among children but not among adults. The development of multiplex PCR technique has provided a new and sensitive method for diagnosing a large panel of viruses. To convince the economical benefits of the rapid viral diagnostic in adult infectious patient, more evidence is needed. In our randomized study, nasal and pharyngeal samples from the patients evaluated at the emergency clinic of internal medicine in the University Hospital of Oulu because of any respiratory symptom, chest pain or fever, will be collected. The samples will be tested for 16 different respiratory viruses by using Anyplex TMII RV16 Detection. The adult participants will be randomized in two groups. In one group the results of the testing will be reported for the attending physician as soon as possible, and in the other group 7 days after sampling. The effect of this delay to patient care is monitored. Also the results of children and adults are compared as well as results of men and women. The hypothesis is that rapid viral diagnostics shortens the length of admission and diminishes the use of bacterial antibiotics. New information on the viral epidemiology among children and adults is provided and clinical manifestations of specific viral infections in adults are described. The estimated 1500 samples are also tested for 5 different respiratory bacteria by Anyplex TM II RB5 Detection. These results will be examined after completion of the study period. The benefits of rapid bacterial detection are evaluated in respect to the clinical course of the disease and considering the infection control aspects as well.
NCT02538770 Respiratory Virus Infection Fever of Unknown Origin Dyspnea Chest Pain Other: Rapid diagnostics using Anyplex TMII RV16 Detection Other: Delayed diagnostics Anyplex TMII RV16 Detection MeSH:Dyspnea Chest Pain Fever of Unknown Origin
HPO:Chest pain Dyspnea Respiratory distress
Primary Outcomes
Description: The number of days in hospital within one month after randomization
Measure: Duration of hospitalization Time: One month
Description: Number of days on antimicrobials within one month after randomization
Measure: Antimicrobial consumption Time: One month
Description: Defined daily doses of antimicrobial agents within one month after randomization
Measure: Antimicrobial consumption Time: One month
Secondary Outcomes
Measure: Number of radiological examinations Time: One month
Measure: Cost of other examinations in hospital Time: One month
2 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial
Primary Outcomes
Description: The number of days in hospital within one month after randomization
Measure: Duration of hospitalization Time: One monthDescription: Number of days on antimicrobials within one month after randomization
Measure: Antimicrobial consumption Time: One monthDescription: Defined daily doses of antimicrobial agents within one month after randomization
Measure: Antimicrobial consumption Time: One monthSecondary Outcomes
Measure: Number of radiological examinations Time: One monthMeasure: Cost of other examinations in hospital Time: One month
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.
NCT04290858 Coronavirus Infections Pneumonia, Viral Dyspnea Drug: Nitric Oxide MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Dyspnea
HPO:Dyspnea Pneumonia Respiratory distress
Primary Outcomes
Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.
Measure: Reduction in the incidence of intubation and mechanical ventilation Time: 28 days
Secondary Outcomes
Description: Mortality from all causes
Measure: Mortality Time: 28 days
Description: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab
Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract Time: 7 days
Description: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).
Measure: Time to clinical recovery Time: 28 days
3 Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19
Primary Outcomes
Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.
Measure: Reduction in the incidence of intubation and mechanical ventilation Time: 28 daysSecondary Outcomes
Description: Mortality from all causes
Measure: Mortality Time: 28 daysDescription: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab
Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract Time: 7 daysDescription: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).
Measure: Time to clinical recovery Time: 28 daysBrief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Acute Respiratory Distress Syndrome and the need for mechanical ventilation. Mortality rates as high as 80% have been reported among those who develop ARDS, despite intensive care and mechanical ventilation. Patients with COVID-19 induced non-Acute Lung Injury who have demonstrated reduction in blood oxygenation, dyspnea, and exercise intolerance but do not require endotracheal intubation and mechanical ventilation will be treated with Aviptadil, a synthetic version of Vasoactive Intestinal Polypeptide (VIP) plus Standard of Care vs. placebo + Standard of Care. Patients will be randomized to intravenous Aviptadil will receive inhaled Aviptadil, 100 μg 3x daily vs. placebo 3x daily. The primary outcome will be progression to ARDS over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFα IL-6 and other cytokines.
NCT04360096 SARS-CoV 2 COVID ARDS ALI Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) Dyspnea Drug: Aviptadil (VIP) Drug: Placebo MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea Lung Injury Wounds and Injuries
HPO:Dyspnea Respiratory distress
Primary Outcomes
Description: Progression to ARDS is defined as the need for mechanical ventilation
Measure: Progression to ARDS Time: 28 days
Secondary Outcomes
Description: Blood PO2 as measured by pulse oximetry
Measure: Blood oxygenation Time: 28 days
Description: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath
= very mild shortness of breath
= mild shortness of breath
= moderate shortness of breath or breathing difficulty
= somewhat severe shortness of breath
= strong or hard breathing
7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity
Measure: RDP Dsypnea Scale Time: 28 days
Description: Distance walked in six minutes
Measure: Distance walked in six minutes Time: 28 days
4 Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial
Primary Outcomes
Description: Progression to ARDS is defined as the need for mechanical ventilation
Measure: Progression to ARDS Time: 28 daysSecondary Outcomes
Description: Blood PO2 as measured by pulse oximetry
Measure: Blood oxygenation Time: 28 daysDescription: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath = very mild shortness of breath = mild shortness of breath = moderate shortness of breath or breathing difficulty = somewhat severe shortness of breath = strong or hard breathing 7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity
Measure: RDP Dsypnea Scale Time: 28 daysDescription: Distance walked in six minutes
Measure: Distance walked in six minutes Time: 28 daysThis was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge. Patients in control group received standard-of-care (consisting of oxygen therapy) alone until discharge.
NCT04378712 Covid-19 Hydrogen/Oxygen Mixed Gas Dyspnea Device: Hydrogen Oxygen Generator with Nebulizer Other: Standard-of-care MeSH:Dyspnea
HPO:Dyspnea Respiratory distress
Primary Outcomes
Description: The proportion of patients with improved disease severity (by at least one scale) at day 2
Measure: The proportion of patients with improved disease severity at day 2 Time: from baseline to day 2
Description: The proportion of patients with improved disease severity (by at least one scale) at day 3
Measure: The proportion of patients with improved disease severity at day 3 Time: from baseline to day 3
Description: The proportion of patients with improved disease severity (by at least one scale) at the day before hospital discharge
Measure: The proportion of patients with improved disease severity at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)
Secondary Outcomes
Description: The change from baseline in oxygen saturation at day 2.
Measure: The change from baseline in oxygen saturation at day 2. Time: from baseline to day 2
Description: The change from baseline in oxygen saturation at day 3.
Measure: The change from baseline in oxygen saturation at day 3. Time: from baseline to day 3
Description: The change from baseline in oxygen saturation at the day before hospital discharge.
Measure: The change from baseline in oxygen saturation at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)
Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in dyspnea scale at day 2. Time: from baseline to day 2
Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in dyspnea scale at day 3. Time: from baseline to day 3
Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in dyspnea scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)
Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2
Measure: The change from baseline in cough scale at day 2 Time: from baseline to day 2
Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3
Measure: The change from baseline in cough scale at day 3 Time: from baseline to day 3
Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge
Measure: The change from baseline in cough scale at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)
Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in chest pain scale at day 2. Time: from baseline to day 2
Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in chest pain scale at day 3. Time: from baseline to day 3
Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in chest pain scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)
Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in chest distress scale at day 2. Time: from baseline to day 2
Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in chest distress scale at day 3. Time: from baseline to day 3
Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in chest distress scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)
5 An International Observational Study of Outpatients With SARS-CoV-2 Infection
Primary Outcomes
Description: The proportion of patients with improved disease severity (by at least one scale) at day 2
Measure: The proportion of patients with improved disease severity at day 2 Time: from baseline to day 2Description: The proportion of patients with improved disease severity (by at least one scale) at day 3
Measure: The proportion of patients with improved disease severity at day 3 Time: from baseline to day 3Description: The proportion of patients with improved disease severity (by at least one scale) at the day before hospital discharge
Measure: The proportion of patients with improved disease severity at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Secondary Outcomes
Description: The change from baseline in oxygen saturation at day 2.
Measure: The change from baseline in oxygen saturation at day 2. Time: from baseline to day 2Description: The change from baseline in oxygen saturation at day 3.
Measure: The change from baseline in oxygen saturation at day 3. Time: from baseline to day 3Description: The change from baseline in oxygen saturation at the day before hospital discharge.
Measure: The change from baseline in oxygen saturation at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in dyspnea scale at day 2. Time: from baseline to day 2Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in dyspnea scale at day 3. Time: from baseline to day 3Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in dyspnea scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2
Measure: The change from baseline in cough scale at day 2 Time: from baseline to day 2Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3
Measure: The change from baseline in cough scale at day 3 Time: from baseline to day 3Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge
Measure: The change from baseline in cough scale at the day before hospital discharge Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in chest pain scale at day 2. Time: from baseline to day 2Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in chest pain scale at day 3. Time: from baseline to day 3Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in chest pain scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.
Measure: The change from baseline in chest distress scale at day 2. Time: from baseline to day 2Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.
Measure: The change from baseline in chest distress scale at day 3. Time: from baseline to day 3Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.
Measure: The change from baseline in chest distress scale at the day before hospital discharge. Time: up to 14 days (from baseline to the day before hospital discharge)The general aim of this study is to estimate the rate of disease progression for adults who seek testing and test positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations, special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-Cov-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.
NCT04385251 COVID COVID19 SARS-CoV 2 Dyspnea Other: Data Collection MeSH:Dyspnea
HPO:Dyspnea Respiratory distress
Primary Outcomes
Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.
Measure: Time to Hospitalization Time: 28 days
Description: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.
Measure: Time to Expiration Time: 28 days
Secondary Outcomes
Description: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.
Measure: Rate of Death at 7 Days Time: 7 days
Description: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.
Measure: Rate of Death at 14 Days Time: 14 days
Description: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.
Measure: Rate of Death at 28 Days Time: 28 days
Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.
Measure: Rate of Hospitalization at 7 Days Time: 7 days
Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.
Measure: Rate of Hospitalization at 14 Days Time: 14 days
Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.
Measure: Rate of Hospitalization at 28 Days Time: 28 days
Description: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.
Measure: Participant Health at 7 Days Time: 7 days
Description: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.
Measure: Participant Health at 14 Days Time: 14 days
Description: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.
Measure: Participant Health at 28 Days Time: 28 days
Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 7 Days Time: 7 Days
Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 14 Days Time: 14 Days
Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 28 Days Time: 28 Days
HPO Nodes
HP:0002098: Respiratory distress
Genes 232
IFT52 CCDC103 COL2A1 KCNA1 COL2A1 SRP54 DNAAF2 ZFPM2 RSPH4A NGLY1 CPT2 COLQ TRAK1 CCNO VAMP1 LGI4 PLCB4 CNTNAP1 EDN1 SPINK1 DISC1 NDUFAF3 COPA TK2 VPS33A LRRC56 SLC25A3 FOXF1 CHAT SLC12A3 ETFDH AIMP2 DPM1 COA8 NKX2-1 SCO2 DNAH11 FOXP3 UBE3B TRPV6 DNAI2 ND4 TACO1 ORC1 SETBP1 SPAG1 GBA HYDIN SLC2A10 XYLT1 DNAH9 COX10 DNAH5 TRNK RPS26 COX20 GATA6 DNAH1 ALDH7A1 ERF DNAI1 SLC5A7 RSPH3 SFTPB CLCNKB SERPING1 DPM2 FASTKD2 CTRC SURF1 MAPT EFEMP2 SLC52A3 CCDC39 MAPT NME8 SDCCAG8 DNAAF4 FGFR1 EFTUD2 ADAMTS13 OTX2 FGFR2 FBP1 DNAJC21 ND3 PRRX1 NKX2-1 BMPER COX6B1 RSPH1 NDUFB11 FGFR2 NDUFB8 COX7B COX8A CCDC114 GNAI3 TUBB4A COQ7 TBC1D24 FBLN5 ARMC4 NAGS TSC1 MMAA SSR4 ITGA3 LYRM4 PRSS1 CFAP300 ADNP ZIC3 STT3B MYO9A TRNL1 ORC6 SPEF2 PRRX1 MPC1 CDC45 CHRNE RUNX2 TRMU TRIP11 LAMB2 OFD1 CCDC151 USP9X FOXJ1 ZMYND10 ND1 SFTPC IL1RN FGFR2 ND6 USP9X TRIP11 GMNN TSC2 ETFA ND2 POMT1 ORC4 ND5 NUP214 TRNE BMPER CDC6 SCO2 DRC1 STK36 GBA DNAAF3 LIFR FAM20C TRNS1 RSPH9 RPGR NDUFS2 IFT81 COL2A1 KAT6A DNAL1 CFAP298 KLHL7 RPS28 SCO1 DNAAF1 CSF2RB PUF60 ATP6 TRNE HCCS ACADVL GAS2L2 AGRN ADCY6 DMPK CFAP221 SNAP25 CSF2RA COL13A1 DNAAF6 FGFR2 DNAAF5 TTC25 STT3B SLC25A1 DNAAF3 PMM2 MMUT MEGF10 SLC35A1 DYNC2LI1 ABCA3 EPHB4 MMUT SIK1 GATA6 STAT5B TRNV DMPK ORC1 NAGS SLC18A3 SOX9 SBDS COX14 EDA LRRC6 COL2A1 GAS8 MMAB TRNN SYT2 EOMES MCIDAS AIFM1 VPS33A HLCS CCDC40 PET100 EP300 DPM2 CDT1 CHAT CREBBP ETFB DNAJB13 CCDC65 TRNW Protein Mutations 1
A118G SNP 1
rs7103572 HP:0002094: Dyspnea
Genes 456
IFT52 CCDC103 COL2A1 GATA6 KCNA1 SRP54 DNAAF2 TET2 TGFB2 CPT2 VCL OPTN RRM2B SCN4A EDN1 SPINK1 DISC1 VPS33A LRRC56 FOXF1 DPM1 STN1 GYG1 LAMC2 NKX2-1 DNAH11 FOXP3 TRPV6 CAV1 ORC1 SETBP1 IRAK1 PPARGC1A GBA HYDIN SLC2A10 SCN1B DNAH9 SQSTM1 CYB5R3 DNASE1L3 COX10 DNAH5 GNAS LRP4 TRNK PRRT2 MRPL3 DNAH1 ALDH7A1 DNAI1 ORC6 CSPP1 COL1A2 SLC5A7 RSPH3 CLCNKB LOX TGFBR2 FASTKD2 CTRC FAM13A SFTPC EFEMP2 UBQLN2 SLC52A3 CCDC39 MAPT SDCCAG8 FUS ACADM OTX2 FGFR2 FBP1 DNAJC21 MATR3 ND3 RAPSN FBN1 NKX2-1 SFTPA2 COX6B1 SMPD1 NDUFB11 CHRNA1 FGFR2 NDUFB8 COX7B COX8A EIF2AK4 FIG4 HLA-DRB1 FBLN5 ARMC4 CHMP2B TSC1 MMAA STAT3 SSR4 LYRM4 CYB5A POLG2 TSC1 ZIC3 STT3B C1R MYL3 FBP1 MPC1 LDLRAP1 HLA-DRB1 SLC25A4 ATXN2 CHRNE ACVRL1 GLA ABCG8 TRMU GNAS LAMB2 CFTR CCDC151 USP9X LAMA3 IRF2BP2 ND1 VCP IL1RN FGFR2 ND6 BCOR ETFA ND2 POMT1 TERT CHRND ALAS2 BMPER CDC6 SCO2 DRC1 WAS STK36 TRMT5 GBA LIFR SH2B3 FAM20C TRNS1 RPGR NDUFS2 VCP TGFB3 DNAL1 CFAP298 RPS28 TET2 ZBTB16 NUMA1 DCTN1 DNAAF1 CSF2RB SMAD4 TRNE TAF15 ACADVL GAS2L2 AGRN SNAP25 CSF2RA FGFR2 STAT5B DNAAF5 GBA C1QA PON1 TTC25 SLC25A1 DNAAF3 PMM2 MMUT MEGF10 CCR6 FLNC SLC35A1 CCN2 DYNC2LI1 PRPH EPHB4 MMUT HLA-DRB1 STAT5B TRNV DMPK SLC18A3 SOX9 SBDS COX14 KCNJ6 NABP1 TREM2 CHRNB1 SMAD3 GTPBP3 MUSK WIPF1 DSC2 DOK7 TRNN PFN1 MCIDAS RARA C9ORF72 HLCS CCDC40 PET100 EP300 NKX2-5 SCN4A SCN4A ENG CHAT CHRNB1 SOD1 GLT8D1 CRELD1 DNAJB13 TRNW SCNN1B ANG GLE1 NEK1 PIGT SCNN1A COL2A1 APOB ZFPM2 RSPH4A NGLY1 COLQ FOXE3 TRAK1 ATRX CCNO NPM1 VAMP1 LGI4 PLCB4 MYBPC3 NR2F2 CNTNAP1 NDUFAF3 ELN SCN5A COPA TK2 SLC25A3 CHAT SLC12A3 CYB5R3 ETFDH AIMP2 PRKAR1A CRLF1 COA8 GAA SCO2 TBX4 FIP1L1 UBE3B DNAI2 ND4 LAMB3 TACO1 SPAG1 CHRNE TWNK PML SFTPC XYLT1 TBL1XR1 SFTPA2 JAK2 TARDBP ISCU MARS1 MYH11 RPS26 STX16 COX20 GATA6 RTEL1 TERT ERF SCNN1G PNKD TERC SFTPB SERPING1 DPM2 GNAS PRKCSH DNA2 SURF1 MAPT NME8 DNAAF4 FGFR1 EFTUD2 UNC13A CHRND NOD2 TBK1 ADAMTS13 PARN PRRX1 CFAP410 BMPER RSPH1 VAPB ARX DBH CCNF TRPM4 CCDC114 GNAI3 TUBB4A ATP11A CAV1 COQ7 TBC1D24 GATA4 TSC2 NAGS DPP9 ITGA3 PRSS1 BMPR2 CFAP300 ERBB4 ADNP MFAP5 EPOR MYO9A TRNL1 ORC6 AGRN SPEF2 PRRX1 CDC45 MAT2A RUNX2 MYH11 SFTPA1 LDLR POLG TRIP11 OFD1 PRKAR1A FOXJ1 MYL2 ZMYND10 CHRNE PLEC SFTPC MGME1 MYLK NEB USP9X COA8 TRIP11 HBB GMNN TSC2 CASR ORC4 ND5 DSP STAT4 NUP214 TRNE HLA-B MGME1 DNAAF3 DNA2 RSPH9 ABCA3 BTNL2 NEFH IFT81 COL2A1 LTBP3 IKZF1 KAT6A KLHL7 DAO SCN5A RNU4ATAC SCO1 PUF60 DNAJB6 ATP6 HCCS TNNC1 PON3 BTNL2 ADCY6 DMPK CFAP221 COL13A1 DNAAF6 AK9 STT3B PGM1 ACTA2 CHCHD10 PRKG1 TTN TGFBR1 MUC5B SERPINA1 IRF5 ABCA3 HNRNPA1 COL13A1 NPPA SIK1 GATA6 SPP1 CHRNA1 CSF2RB ORC1 NAGS EPHA4 EDA LRRC6 MUC5B PON2 COL2A1 GAS8 MMAB SYT2 EOMES SLC25A1 JPH2 PCSK9 ANXA11 AIFM1 VPS33A DPM2 ABCG5 CDT1 CREBBP ETFB TRNK CCDC65 Protein Mutations 0
SNP 0
Primary Outcomes
Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.
Measure: Time to Hospitalization Time: 28 daysDescription: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.
Measure: Time to Expiration Time: 28 daysSecondary Outcomes
Description: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.
Measure: Rate of Death at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.
Measure: Rate of Death at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.
Measure: Rate of Death at 28 Days Time: 28 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.
Measure: Rate of Hospitalization at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.
Measure: Rate of Hospitalization at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.
Measure: Rate of Hospitalization at 28 Days Time: 28 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.
Measure: Participant Health at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.
Measure: Participant Health at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.
Measure: Participant Health at 28 Days Time: 28 daysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 7 Days Time: 7 DaysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 14 Days Time: 14 DaysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 28 Days Time: 28 Days